Maintenance treatment with Lanreotide in Patients with small cell lung cancer (LD/ED) expressing SST receptors, responsive to a first line standard chemotherapy/radiotherapy.

Trial Profile

Maintenance treatment with Lanreotide in Patients with small cell lung cancer (LD/ED) expressing SST receptors, responsive to a first line standard chemotherapy/radiotherapy.

Recruiting
Phase of Trial: Phase III

Latest Information Update: 09 Sep 2015

At a glance

  • Drugs Lanreotide (Primary)
  • Indications Small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 09 Sep 2015 Interim results (n=53) presented at the 16th World Conference on Lung Cancer.
    • 28 Nov 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top